Modafinil

Modafinil is a eugeroic, or wakefulness-promoting agent, best known under the brand name Provigil. It was developed in France by Lafon Laboratories, growing out of research on the earlier compound adrafinil, and it reached the market as a treatment for excessive sleepiness ^[1]. The United States Food and Drug Administration approved it in 1998 for narcolepsy and later for obstructive sleep apnea and shift-work sleep disorder; in the United States it is a Schedule IV controlled substance, reflecting a recognized but relatively low potential for misuse ^[2].

Pharmacologically, modafinil is distinct from amphetamine-type stimulants. Rather than forcing a large release of neurotransmitter, it promotes a stable, wake-like state that preserves the ability to sleep once the drug wears off, which is part of why it earned a reputation for a smoother, cleaner feel ^[4]. Its single-enantiomer relative armodafinil is the longer-lasting R-form of the same molecule.

Beyond its approved sleep indications, modafinil is used very widely off-label as a cognitive enhancer by students, professionals, and shift workers. A systematic review of healthy, non-sleep-deprived users concluded that it reliably improves executive function and, on more demanding tasks, attention and learning, without prominent mood disturbance ^[1]. In sleep-deprived people it can restore performance and alertness toward well-rested levels ^[6].

Regulatory status is therefore clear: modafinil is an approved prescription medicine in the United States, Europe, and many other regions, dispensed as oral tablets, while its widespread nootropic use falls outside those approvals. It has also become the template for a family of research-chemical analogs such as fluorinated and hydroxylated derivatives ^[2].

REGULATORY STATUS. United States: Schedule IV controlled substance, approved 1998, indicated for excessive sleepiness associated with narcolepsy, obstructive sleep apnea, and shift work disorder. European Union: indication is narrower, restricted to narcolepsy only. Sport: WADA lists modafinil under S6.A as a non-specified stimulant, prohibited in competition; it has been on the list since 2004.

SERIOUS ADVERSE EFFECTS (from the PROVIGIL label). Serious rash requiring hospitalisation and discontinuation has been reported; the label instructs discontinuation at the first sign of rash unless clearly unrelated. Stevens-Johnson syndrome, toxic epidermal necrolysis, and DRESS have been reported in postmarketing experience. In pediatric clinical trials, rash leading to discontinuation occurred in approximately 0.8% (13 of 1,585), and this dermatologic risk contributed to the FDA declining the pediatric ADHD application. Angioedema and anaphylaxis have been reported. Psychiatric adverse reactions include mania, delusions, hallucinations, and suicidal ideation; particular caution is advised in patients with a history of psychosis, depression, or mania.

COMMON ADVERSE EFFECTS. Headache is the most common, then nausea, nervousness, insomnia, anxiety, decreased appetite, and blood pressure elevation.

DRUG INTERACTIONS. This is the most practically important and most frequently overlooked item. Modafinil induces CYP3A4/5, so the effectiveness of steroidal contraceptives may be reduced during treatment and for one month after stopping; alternative or additional non-hormonal contraception is required. Modafinil inhibits CYP2C19, so exposure to phenytoin, diazepam, propranolol, omeprazole, and clomipramine may increase. Because it both induces and inhibits several cytochrome P450 isoenzymes, interaction potential spans many drug classes (PMID 18729534).

PREGNANCY. Genuinely unresolved and the two main datasets disagree. The manufacturer's Provigil/Nuvigil registry found major congenital malformations in 13% of 102 prospective live births against a roughly 3% background rate (PMID 33074297), and that signal drove EU and other regulators in 2019 to contraindicate modafinil in pregnancy and in females of reproductive potential not using effective non-hormonal contraception. The independent Swedish and Norwegian population registry, however, found 2.6% versus 2.1% with a crude risk ratio of 1.06 (95% CI 0.35 to 3.26) and did not confirm it (PMID 32870289). Both studies are small; 133 exposed pregnancies cannot exclude a meaningful effect. The practical guidance in the literature is to stop modafinil before pregnancy.

ABUSE AND DEPENDENCE. Modafinil raises dopamine in the nucleus accumbens in humans, which is the pharmacological signature of drugs with abuse potential, and the authors of that study explicitly called for heightened awareness of abuse and dependence risk in vulnerable populations (PMID 19293415). In practice reported dependence cases remain few relative to other psychostimulants, and this discrepancy is unexplained (PMID 38467484). It does not treat cataplexy.

Modafinil is a documented inducer of CYP3A4/5 and can lower plasma concentrations of drugs cleared by that enzyme; the FDA label specifically warns that it reduces the effectiveness of steroidal contraceptives (oral, implant, and hormonal devices), so an alternative or additional non-hormonal method is advised during use and for one month after discontinuation, and it can similarly reduce cyclosporine and triazolam exposure.

It also inhibits CYP2C19, which can raise levels of substrates such as phenytoin, diazepam, propranolol, and some tricyclic antidepressants and SSRIs, an effect that is exaggerated in CYP2C19 poor metabolizers. Coadministration with warfarin warrants closer INR monitoring per the label. Combining modafinil with other sympathomimetic stimulants or with MAO inhibitors should be approached cautiously given additive cardiovascular and pressor potential. This is research information, not medical advice.

Checking a whole stack? Run it through interactions + stacks.

Modafinil was discovered in the late 1970s in France, emerging from work by the neurophysiologist Michel Jouvet and Lafon Laboratories on a series of benzhydryl sulfinyl compounds that also included its precursor adrafinil. It was first offered in France during the 1990s and gained United States Food and Drug Administration approval in 1998, marketed as Provigil, for the excessive sleepiness of narcolepsy. Its indications later expanded to shift-work sleep disorder and residual sleepiness in obstructive sleep apnea. Over the following decades it became the most extensively studied pharmacological cognitive enhancer, and human imaging work clarified that its wake-promoting action operates substantially through the dopamine transporter.

Modafinil holds a distinctive reputation as the benchmark eugeroic, widely valued for delivering hours of steady, clear-headed wakefulness without the jitteriness and sharp crash associated with classical stimulants. It is one of the few nootropics backed by a large body of controlled clinical trials, and reviews of healthy users find modest but real gains in attention, executive function, and learning rather than raised raw intelligence. Its favorable tolerability and well-defined mechanism make it among the most credible performance compounds available. At the same time, the same dopaminergic action underlies a recognized, if modest, potential for dependence, which is why it remains a controlled prescription substance. Rare but serious skin reactions are also part of its documented safety profile.